The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.

ABSTRACT:

Aims

The aim of the present study was to investigate whether selective antagonism of the cysteine-X-cysteine chemokine receptor-2 (CXCR2) receptor has any adverse effects on the key innate effector functions of human neutrophils for defence against microbial pathogens.

Methods

In a double-blind, crossover study, 30 healthy volunteers were randomized to treatment with the CXCR2 antagonist AZD5069 (100 mg) or placebo, twice daily orally for 6 days. The peripheral blood neutrophil count was assessed at baseline, daily during treatment and in response to exercise challenge and subcutaneous injection of granulocyte-colony stimulating factor (G-CSF). Neutrophil function was evaluated by phagocytosis of Escherichia coli and by the oxidative burst response to E. coli.

Results

SUBMITTER: Jurcevic S 

PROVIDER: S-EPMC4693488 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature